Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Q3 2022 DANYELZA® record product revenues of $12.5 million , YoY growth of 40% and 28% sequential increase compared to Q2 2022 DANYELZA marketing authorization granted in Israel ; regulatory filing submitted in Brazil Management reiterates financial guidance, including anticipated 2022 full-year

Nov 07, 2022

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

NEW YORK , Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022 , on Monday, November 7, 2022 , after the close of the U.S. financial markets.

Nov 02, 2022

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

NEW YORK , Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Oct 28, 2022

Y-mAbs Announces Pivotal Data for Omburtamab

NEW YORK , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Oct 03, 2022

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

NEW YORK , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Adium

Sep 26, 2022

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

NEW YORK , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Sep 01, 2022

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of

Aug 30, 2022

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Omburtamab BLA Accepted by the FDA with November 2022 PDUFA date Announced IND Clearance for the first GD2-SADA construct YTD DANYELZA® product revenue $20.3 million Management reiterates financial guidance, including 2022 full-year DANYELZA® revenue of $45-$50 million Strong cash position with

Aug 08, 2022

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended June 30, 2022 , on Monday, August 8, 2022 , after the close of the U.S. financial markets.

Aug 02, 2022

Y-mAbs’ Announces Clearance of IND for GD2-SADA

NEW YORK , July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Jul 12, 2022

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21